...
首页> 外文期刊>International Journal of Hematology and Oncology >Salvage Stereotactic Body Radiosurgery in the Management of Recurrent Gynecological Cancer
【24h】

Salvage Stereotactic Body Radiosurgery in the Management of Recurrent Gynecological Cancer

机译:挽救立体定向放射外科治疗复发性妇科癌症

获取原文
           

摘要

Local tumor persistence in the pelvis is the major cause of death in patients with recurrent gynecological cancer. Pelvic exenteration has been the only treatment option providing a chance for cure in selected patients. The aim of this study is to analyze the efficacy of stereotactic body radiosurgery (SBRS) in patients with recurrent gynecological cancer. Sixteen patients treated with SBRS were analyzed retrospectively. The majority of the patients had cervical cancer. Eleven patients had a history of prior radiotherapy either as postoperative adjuvant external beam radiotherapy (EBRT) with a median dose of 50.4 Gy (range 45-60 Gy) or definitive chemoradiotherapy as EBRT and high dose rate brachytherapy with a dose of 85-90 Gy low dose rate equivalent to point A. The prescribed dose of SBRS was 15-40 Gy (mean 26.6 Gy) in 3-5 fractions. Five patients with no prior radiotherapy received additional EBRT before SBRS. The median follow-up in all patients is 12 months (range 3-36 months). Six patients (37.5%) showed complete radiological and functional response to salvage SBRS. Six patients (37.5%) showed partial response and 2 (12.5%) showed stable disease. One and 2 year overall survival rates are 60.3% and 40.2% respectively. Progression free survival is 59%. All patients with complete response after SBRS are alive with no evidence of disease with a median follow up time of 20 months. SBRS is a promising treatment modality with high local control and reasonable complication rates in selected patients with recurrent gynecological cancer.
机译:骨盆中局部肿瘤的持久性是复发性妇科癌症患者死亡的主要原因。盆腔穿刺术是唯一为某些患者提供治愈机会的治疗方法。这项研究的目的是分析立体定向放射外科(SBRS)在复发性妇科癌症患者中的疗效。回顾性分析了16例接受SBRS治疗的患者。大多数患者患有宫颈癌。 11位患者曾接受过放疗史,或者是术后辅助外束放疗(EBRT),中位剂量为50.4 Gy(范围45-60 Gy),或者是明确的放化疗,如EBRT和高剂量率近距离放疗,剂量为85-90 Gy SBRS的规定剂量为15至40 Gy(平均26.6 Gy),分为3-5个部分。五名没有进行过放射治疗的患者在SBRS之前接受了额外的EBRT。所有患者的中位随访时间为12个月(范围3-36个月)。 6名患者(37.5%)对抢救性SBRS表现出完全的放射学和功能反应。 6名患者(37.5%)表现出部分缓解,2名(12.5%)表现出稳定的疾病。一年和两年的总生存率分别为60.3%和40.2%。无进展生存率为59%。所有在SBRS后完全缓解的患者都还活着,没有疾病的迹象,中位随访时间为20个月。 SBRS是一种在某些复发性妇科癌症患者中具有高度局部控制和合理并发症发生率的有前途的治疗方式。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号